About: A narrative review of emerging therapeutics for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A narrative review of emerging therapeutics for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A narrative review of emerging therapeutics for COVID-19
Creator	Jackson, Gretchen Weeraratne, Dilhan Arriaga, Yull Reyes, Fredy Willis, Van
Source	Elsevier; Medline; PMC
abstract	Abstract The novel coronavirus SARS-CoV-2, causal agent of COVID-19, quickly spread around the world resulting in the most aggressive pandemic experienced in over 100 years. Research into targeted therapies and vaccines has been initiated on an unprecedented scale and speed but will take months and even years to come to fruition. Meanwhile, the efficacy of emerging therapeutics for use in treating COVID-19 is feverishly being investigated to identify the best available treatment options for dealing with the current wave of disease. This review provides frontline clinicians with a pragmatic summary of the current state of the rapidly evolving evidence supporting emerging candidate therapeutics for COVID-19. Two main categories of pharmaceutical therapeutics are showing promise—those with antiviral activity directly addressing infection and those that counteract the inflammatory cytokine storm induced by severe disease. Preliminary results suggest that other approaches such as convalescent plasma therapy and lung radiation therapy may have some efficacy. The current clinical evidence for potential treatments is preliminary – often small retrospective series or early results from randomized trials – and the science is evolving rapidly. Long-term results from large, well-designed randomized trials will provide definitive evidence of therapeutic effectiveness and are likely months away. The trial landscape for promising therapies is described.
has issue date	2020-07-20(xsd:dateTime)
bibo:doi	10.1016/j.mayocpiqo.2020.07.004
bibo:pmid	32838206
has license	els-covid
sha1sum (hex)	f9c32e8afdaad367ef4c5950e652e31494f5925a
schema:url	https://doi.org/10.1016/j.mayocpiqo.2020.07.004
resource representing a document's title	A narrative review of emerging therapeutics for COVID-19
has PubMed Central identifier	PMC7369591
has PubMed identifier	32838206
schema:publication	Mayo Clin Proc Innov Qual Outcomes
resource representing a document's body	covid:f9c32e8afdaad367ef4c5950e652e31494f5925a#body_text
is schema:about of	named entity 'trial' named entity 'efficacy' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID-19' named entity 'Journal' named entity '100' named entity 'SUMMARY' named entity 'INDUCED' named entity 'DIRECTLY' named entity 'LANDSCAPE' named entity 'THERAPEUTICS' named entity 'INFLAMMATORY CYTOKINE' named entity 'AWAY' named entity 'TO IDENTIFY' named entity 'SCALE' named entity 'EVIDENCE' named entity 'LONG-TERM' named entity 'CORONAVIRUS SARS' named entity 'retrospective' named entity 'current' named entity 'cytokine storm' named entity 'evidence' named entity 'effectiveness' named entity 'efficacy' named entity 'rapidly' named entity 'aggressive' named entity 'Research' named entity 'treating' named entity 'Meanwhile' named entity 'randomized trials' named entity 'COVID-19' named entity 'randomized trials' named entity 'convalescent plasma therapy' named entity 'treatment options' named entity 'COVID-19' named entity 'IL6' named entity 'HCQ' named entity 'mortality rates' named entity 'HCQ' named entity 'COVID-19' named entity 'HCQ' named entity 'JAK inhibitor' named entity 'observational study' named entity 'COVID' named entity 'infection' named entity 'COVID' named entity 'RCT' named entity 'National Library of Medicine' named entity 'HCQ' named entity 'Italy' named entity 'COVID' named entity 'CPT' named entity 'antiviral therapies' named entity 'infection' named entity 'glucocorticoid' named entity 'knowledge graph' named entity 'data safety and monitoring board' named entity 'double-blind, placebo-controlled' named entity 'case reports' named entity 'interleukin 6' named entity 'mechanism of action' named entity 'hyperinflammation' named entity 'HCQ' named entity 'COVID-19 pandemic' named entity 'infection' named entity 'SARS-CoV-2' named entity 'tocilizumab' named entity 'knowledge integration' named entity '10 million' named entity 'IL6' named entity 'COVID' named entity 'randomized, double-blind' named entity 'pre-print' named entity 'COVID-19 vaccine' named entity 'tocilizumab' named entity 'randomized trial'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software